H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Intellia Therapeutics today and set a price target of $25.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Kapoor is a 4-star analyst with an average return of 11.7% and a 41.86% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Halozyme, and Summit Therapeutics.

In addition to H.C. Wainwright, Intellia Therapeutics also received a Buy from Chardan Capital’s Geulah Livshits in a report issued on February 27. However, on the same day, Bank of America Securities reiterated a Hold rating on Intellia Therapeutics (NASDAQ: NTLA).

Based on Intellia Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $95.79 million. In comparison, last year the company earned a revenue of $12.87 million and had a GAAP net loss of $128.9 million

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTLA in relation to earlier this year. Most recently, in January 2026, Michael P Dube, the VP & CAO of NTLA sold 2,989.00 shares for a total of $27,528.69.